Answers are grounded in this paper and cite their sources.
Reveals absent fibrinolytic activity in subarachnoid hemorrhage, suggesting antifibrinolytic therapy should not be administered during high-risk rebleeding periods.
Fibrinolytic activity of cerebrospinal fluid and peripheral blood was studied in 14 patients with subarachnoid hemorrhage during the high-risk period of subarachnoid rebleeding. Fibrinolytic activity of cerebrospinal fluid or peripheral blood could not be demonstrated. Determination of fibrin degradation products showed high levels in cerebrospinal fluid, being a result of meningeal irritation. The findings in this study--as well as other observations--suggest, that antifibrinolytic therapy should not be administered in patients with subarachnoid hemorrhage.
No takes yet. Share an insight, caveat, or question.
Steinmetz et al. (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: